[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650313":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":51,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":68,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"University of Kragujevac","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Locally Advanced Cervical Cancer Cohort",null,"Patients with histopathologically confirmed locally advanced cervical cancer, FIGO 2018 stage IIB-IVA, treated with definitive concurrent chemoradiotherapy. Pretreatment vitamin D concentrations will be measured in serum and cervical lavage fluid before treatment initiation, and patients will be followed for treatment response and acute radiation toxicity.",[13],"Diagnostic Test: Pretreatment Vitamin D Assessment in Serum and Cervical Lavage Fluid",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Pretreatment Vitamin D Assessment in Serum and Cervical Lavage Fluid","Vitamin D concentrations will be measured before the initiation of definitive chemoradiotherapy in serum and cervical lavage fluid using chemiluminescence, as the standard institutional laboratory method. Baseline vitamin D levels will be analyzed in relation to treatment response, acute radiation toxicity, and selected clinical, morphological, treatment-related, and socio-demographic parameters.",[9],[21],{"name":22,"affiliation":23,"role":24},"Marija Živković Radojević, MD, PhD, Radiation Oncologist","Faculty of Medical Sciences, University of Kragujevac, Serbia, University Clinical Centre Kragujevac, Center for radiation oncology","PRINCIPAL_INVESTIGATOR",[26,30],{"name":22,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","+381658384450","makizivkovicmarija@gmail.com",{"name":31,"role":27,"phone":32,"phoneExt":10,"email":33},"Neda Milosavljević, MD, PhD, Radiation Oncologist","+381638429691","neda.milosavljevic@yahoo.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"University Clinical Center Kragujevac","RECRUITING","Kragujevac","Šumadija","34000","Serbia","RS",{"type":44,"coordinates":45},"Point",[46,47],20.91667,44.01667,{"lat":47,"lon":46},[50],{"name":22,"role":27,"phone":28,"phoneExt":10,"email":29},{"type":24,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Marija Zivkovic Radojevic","Assistant Professor","100650313","vitamin-d-status-and-clinical-outcomes-in-locally-advanced-cervical-cancer-100650313",false,"NCT07743918","Vitamin D Status and Clinical Outcomes in Locally Advanced Cervical Cancer","Pretreatment Vitamin D Status and Clinical Outcomes in Patients With Locally Advanced Cervical Cancer Undergoing Definitive Chemoradiotherapy","CERVITAL","Inclusion Criteria:\n\n* Female patients aged 18 to 80 years.\n* Histopathologically confirmed cervical cancer.\n* Locally advanced disease, FIGO 2018 stage IIB to IVA.\n* Eastern Cooperative Oncology Group performance status 0-1.\n* Planned treatment with definitive concurrent chemoradiotherapy.\n* Signed informed consent.\n* Ability to comply with study procedures and follow-up visits.\n\nExclusion Criteria:\n\n* Age under 18 years.\n* Pregnancy or lactation.\n* Previous or synchronous diagnosis of another pelvic or abdominal malignancy.\n* Previous chemotherapy.\n* Previous radiotherapy.\n* Previous treatment with immune checkpoint inhibitors.\n* Current or recent vitamin D supplementation.\n* Interrupted oncological treatment.\n* Failure to attend scheduled follow-up visits.\n* Incomplete medical documentation.","FEMALE","18 Years","80 Years",{"count":66,"type":67},100,"ESTIMATED","7 Months","OBSERVATIONAL","Background. Definitive chemoradiotherapy represents the standard therapeutic approach for the management of locally advanced cervical cancer. Vitamin D plays an important role in the regulation of cellular growth and differentiation, immune system function, and the modulation of inflammatory processes. Hypovitaminosis D may be associated with the development of cervical cancer, whereas its impact on the effects of oncological treatment remains insufficiently elucidated. The aim of this study is to investigate the predictive significance of vitamin D in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy.\n\nMethods. This study is designed as a clinical, observational, prospective cohort study. Patients with locally advanced cervical cancer undergoing definitive chemoradiotherapy at the Clinic for Radiation Oncology, University Clinical Center Kragujevac, will be enrolled. Vitamin D concentrations will be measured before the initiation of treatment in both serum and cervical lavage samples. Baseline vitamin D levels will be analyzed in relation to treatment outcome and the occurrence of acute radiation toxicity. In addition, vitamin D concentrations will be evaluated in the context of clinical and morphological parameters, therapeutic response, and treatment-related toxicity.\n\nExpected Results. This study will enable an assessment of the actual significance of pretreatment vitamin D concentrations in serum and cervical lavage as a potential novel biomarker in relation to chemoradiosensitivity and\u002For chemoradioresistance of cervical cancer, as well as the response of organs at risk, in patients with locally advanced disease.",[72,73],"Locally Advanced Cervical Cancer","Vitamin D Concentration",[75,76,77,78,79,80,81,82,83,84,85,86,87,88,89],"Locally advanced cervical cancer;","vitamin D;","hypovitaminosis D;","serum vitamin D;","cervical lavage;","chemoradiotherapy;","radiotherapy;","cisplatin;","brachytherapy;","treatment response;","radiation toxicity;","RECIST 1.1;","CTCAE;","chemoradiosensitivity;","chemoradioresistency","2026-07-31",{"date":92,"type":93},"2026-08-04","ACTUAL",{"date":95,"type":93},"2026-01-01",{"date":97,"type":67},"2034-09-01",{"name":5,"class":6},1]